| Active substance |
Temozolomide |
| Also known as |
TMZ, Methazolastone |
| Blood pressure |
No direct effect |
| Chemical name |
3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide |
| Dosage (medical) |
Typically 150-200 mg/mВІ per day for 5 days every 28 days cycle |
| Dosage (sports) |
Not applicable |
| Effects |
Antitumor effect, crosses the blood-brain barrier |
| Formula |
C6H6N6O2 |
| Half-life |
1.8 hours |
| Hepatotoxicity |
Low |
| Lab Test |
CBC (Complete Blood Count) monitoring |
| Main action |
Antineoplastic |
| Side effects |
Nausea, vomiting, constipation, loss of appetite, alopecia, headache, fatigue, neutropenia, thrombocytopenia |
| Storage conditions |
Store at controlled room temperature, 20-25В°C (68-77В°F) |
| Strength |
100mg |
| Substance class |
Alkylating agent |
| Trade name |
Temodar, Temodal, Temcad |
| Use in sports |
None |
| Water Retention |
No significant impact |
| Manufacturer |
Cipla Ltd. |
| Packing |
5 caps/bottle |
